Hippocampal inflammation and depression in multiple sclerosis: integrating evidence from TSPO PET and resting state fMRI by Colasanti, A et al.
 Abstract Preview - Step 3/4- print version -  
 
Topic: 20. Imaging
Title: Hippocampal inflammation and depression in multiple sclerosis: integrating evidence from
TSPO PET and resting state fMRI
Author(s): A. Colasanti1,2, Q. Guo3, P. Giannetti1, M. Wall3, R.D. Newbould3, C. Bishop3, M. Onega3, R.
Nicholas4, O. Ciccarelli5, P. Muraro1, O. Malik4, D. Owen1, A.H. Young2, R. Gunn3, P. Piccini1, P.M.
Matthews1, E.A. Rabiner3
Institute(s): 1Imperial College London, Division of Brain Sciences, 2Institute of Psychiatry, Psychology &
Neuroscience; King's College London, 3Imanova Ltd, 4Imperial College Healthcare NHS Trust,
5Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom
Text: Depression is highly prevalent in patients with multiple sclerosis (MS) and is associated more
generally with elevated inflammatory markers, suggesting common pathophysiological
mechanisms. The hippocampus is implicated in the pathophysiology of depression and is
susceptible to neuroinflammation in MS. We hypothesise that the high prevalence of depression in
MS is a consequence of the chronic immune activation in the hippocampus.
We characterized the relationship between depressive symptoms and hippocampal microglial
activation in MS patients using the 2nd generation TSPO radioligand [18F]-PBR111. To evaluate
pathophysiological mechanisms, we explored the relationships between hippocampal inflammation,
depressive symptoms and hippocampal functional connectivity as defined by resting state fMRI.
11 patients with multiple sclerosis and 22 healthy controls were administered the Beck's Depression
Inventory (BDI) and were genotyped for the SNP rs6971 of the TSPO gene, prior to PET and fMRI
scanning. The Distribution Volume Ratio (DVR) of [18F]-PBR111 in the hippocampus was estimated
as an index of activated microglia density. For the analysis of functional connectivity, the
hippocampus was used as the seed region. We compared [18F]-PBR111 uptake in the
hippocampus of MS patients relative to healthy controls and examined the correlations between
[18F]-PBR111 uptake, BDI scores, and hippocampal functional connectivities in patients with MS.
[18F]-PBR111 DVR was higher in the hippocampus of MS patients relative to healthy controls
(F=5.73; p=0.024) and in MS patients the hippocampal DVR was correlated with the intensity of
depressive symptoms (r=0.86, p=0.006). The strength of hippocampal functional connectivity to
prefrontal regions, including the subgenual cingulate, and parietal regions, such as posterior
cingulate and precuneus, correlated with both depressive symptoms and [18F]-PBR111 DVR (p<
0.05 or z=2.3; cluster-corrected for multiple comparisons).
Our results provide evidence that hippocampal microglial activation in MS impairs the brain
functional connectivities in regions contributing to maintenance of a normal affective state. They
suggest a rationale for the responsiveness of depression in some people with MS to effective
control of brain inflammation.
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